Ambit Biosciences is a privately-held biopharmaceutical company engaged in the discovery and development of small molecule kinase inhibitors for the treatment of cancer, inflammatory disease, and other indications. Ambit's lead compound, AC220, is a novel, potent, highly selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3) inhibitor, and is currently under clinical investigation in patients with relapsed or refractory AML. Ambit is developing AC220 in collaboration with Astellas Pharma Inc. as part of a worldwide agreement to jointly develop and commercialize FLT3 kinase inhibitors in oncology and non-oncology indications. In addition to AC220, Ambit's clinical pipeline includes AC480, a pan-HER inhibitor, and AC430, an oral JAK2 inhibitor. Ambit also has a pipeline of preclinical candidates which includes CEP-32496, a BRAF inhibitor licensed to Cephalon.
Current Team (4)Update
Past Team (4)Update
Funding Rounds (5) - $113.4MUpdate
Board Members and Advisors (8)Update
Independent investment company
Venture Capital Firm
Venture capital Firm
The Roche Venture Fund is the name given to the corporate venture fund of the healthcare company...
Canadian Venture Capital Firm
OrbiMed is a healthcare-dedicated investment firm, with approximately $5 billion in assets under...
Healthcare and Life Sciences Investment
4215 Sorrento Valley Blvd.
San Diego, CA 92121